ViMRT
}  
 
Home   
< Docs   

 HBV mutation literature information.


  [Resistance to adefovir in patients with chronic hepatitis B].
 PMID: 17237626       2006       The Korean journal of hepatology
Abstract: Two major mutations of adefovir resistance are rtN236T and rtA181V/T.


  Virological response and incidence of adefovir resistance in lamivudine-resistant patients treated with adefovir dipivoxil.
 PMID: 17310821       2006       Antiviral therapy
Abstract: Of the 46 patients, 11 had ADV resistance (5 rtN236T, 5 rtA181T, 1 rtA181T and rtN236T).


  Susceptibility to antivirals of a human HBV strain with mutations conferring resistance to both lamivudine and adefovir.
 PMID: 15915463       2005       Hepatology (Baltimore, Md.)
Abstrac
Abstract: Considering the use of de novo or add-on 3TC+ADV bitherapy, we investigated the possibility of the emergence of an HBV strain harboring polymerase mutations conferring resistance to both 3TC (rtL180M+M204V) and ADV (rtN236T).
Abstract: In conclusion, the combination of rtL180M+M204V and rtN236T mutations impairs HBV replication and confers resistance to both 3TC and ADV in vitro.


  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B.
 PMID: 15987916       2005       The New England journal of medicine
Abstract: Resistance mutations rtN236T and rtA181V were identified in 5.9 percent of patients after 144 weeks.


  Chronic hepatitis B--treatment with nucleoside analogues.
 PMID: 16108169       2005       The Medical journal of Malaysia
Abstract: Adefovir-resistant mutants (rt N236T) are susceptible to lamivudine and entecavir.


  Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation.
 PMID: 16168522       2005       Journal of hepatology
Abstract: RESULTS: Eight male patients with pre-existing lamivudine resistance or breakthrough (mean age 47+/-13 years) were found to have adefovir-resistant mutations rtA181V/T or rtN236T.


  The current management of HBV drug resistance.
 PMID: 16461216       2005       Journal of clinical virology
Abstract: The overall incidence of adefovirresistant rtN236T and A181V is low, being 0 after one year and 5.9% after 3 years' therapy.


  Comparisons of the HBV and HIV polymerase, and antiviral resistance mutations.
 PMID: 15134177       2004       Antiviral therapy
Abstract: Recently, resistance to adefovir has also been described in the D Domain at rtN236T.


  Molecular mechanisms of adefovir sensitivity and resistance in HBV polymerase mutants: a molecular dynamics study.
 PMID: 15261293       2004       Bioorganic & medicinal chemistry letters
Abstract: In the case of rtN236T mutant, loss of two hydrogen bonds accompanied by significant decrease in electrostatic interactions is observed, which explains the observed decrease in drug sensitivity and binding affinity of adefovir diphosphate toward the rtN236T mutant HBV polymerase.


  Successful therapy of hepatitis B with tenofovir in HIV-infected patients failing previous adefovir and lamivudine treatment.
 PMID: 15577546       2004       AIDS (London, England)
Abstract: Surprisingly, adefovir therapy failed, although none of the virus isolates displayed mutations known to be associated with adefovir resistance (A181V, N236T).



Browser Board

 Co-occurred Entities




   Filtrator